CN109512837A - A kind of lactic acid hemodialysis concentrated solution and preparation method thereof - Google Patents
A kind of lactic acid hemodialysis concentrated solution and preparation method thereof Download PDFInfo
- Publication number
- CN109512837A CN109512837A CN201811613320.9A CN201811613320A CN109512837A CN 109512837 A CN109512837 A CN 109512837A CN 201811613320 A CN201811613320 A CN 201811613320A CN 109512837 A CN109512837 A CN 109512837A
- Authority
- CN
- China
- Prior art keywords
- liquid
- haemodialysis
- lactic acid
- concentration
- concentrated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001631 haemodialysis Methods 0.000 title claims abstract description 90
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 90
- 239000004310 lactic acid Substances 0.000 title claims abstract description 45
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 45
- 230000000322 hemodialysis Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 61
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 30
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims abstract description 28
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 28
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 28
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 15
- 239000001110 calcium chloride Substances 0.000 claims abstract description 15
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 15
- 239000011780 sodium chloride Substances 0.000 claims abstract description 15
- 229910001629 magnesium chloride Inorganic materials 0.000 claims abstract description 14
- 239000001103 potassium chloride Substances 0.000 claims abstract description 14
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 14
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 235000011148 calcium chloride Nutrition 0.000 claims abstract description 3
- 235000011147 magnesium chloride Nutrition 0.000 claims abstract description 3
- 235000002639 sodium chloride Nutrition 0.000 claims abstract description 3
- 238000000502 dialysis Methods 0.000 claims description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 238000005660 chlorination reaction Methods 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 229960000583 acetic acid Drugs 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- PQZLMOYBGBWNEY-UHFFFAOYSA-M potassium;carbonic acid;chloride Chemical compound [Cl-].[K+].OC(O)=O PQZLMOYBGBWNEY-UHFFFAOYSA-M 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of lactic acid hemodialysis concentrated solution and preparation method thereof, the lactic acid hemodialysis concentrated solution includes haemodialysis concentration A liquid and haemodialysis concentration B liquid: the haemodialysis concentration A liquid is by following material composition: sodium chloride, potassium chloride, calcium chloride, magnesium chloride, lactic acid and water；The haemodialysis concentration B liquid is by following material composition: sodium bicarbonate and water.The present invention provides a kind of lactic acid hemodialysis concentrated solution and preparation method thereof, and the lactic acid hemodialysis concentrated solution production process is nonirritant to eye nose to people close friend.
Description
Technical field
The present invention relates to hemodialysis concentrated solution fields.It is more particularly related to which a kind of lactic acid haemodialysis is dense
Contracting liquid and preparation method thereof.
Background technique
Haemodialysis (HD) is one of acute or chronic renal failure kidneys of patients Replacement Therapy.It is by by internal blood
Liquid is drained in vitro, through one by the dialyzer that is formed without several hollow fibres, blood electrolysis similar with concentration containing body
Matter solution (dialyzate) carries out electrolyte balance inside and outside hollow fibre one by one, through disperse, concentration gradient and convective principles,
It takes away intracorporal metabolic waste, maintain electrolyte and acid-base balance；Moisture excessive in vivo is removed simultaneously, and whole process is known as blood
Liquid dialysis.The formula of existing hemodialysis concentrated solution is to use glacial acetic acid as Ph regulator, and glacial acetic acid itself does not have human body
Benefit, weakly acidic and corrosion is strong in aqueous solution, to eye and the irritant effect of nose, production process glacial acetic acid strong impulse
Smell can allow people extremely uncomfortable.
Summary of the invention
The object of the present invention is to provide a kind of lactic acid hemodialysis concentrated solution and preparation method thereof, the lactic acid haemodialysis is dense
Contracting liquid production process is nonirritant to eye nose to people close friend.
In order to realize these purposes and other advantages according to the present invention, a kind of lactic acid hemodialysis concentrated solution is provided,
A liquid is concentrated including haemodialysis and B liquid is concentrated in haemodialysis:
Haemodialysis concentration A liquid is by following material composition: sodium chloride, potassium chloride, calcium chloride, magnesium chloride, lactic acid and
Water；
The haemodialysis concentration B liquid is by following material composition: sodium bicarbonate and water.
Preferably, in a kind of lactic acid hemodialysis concentrated solution, the haemodialysis concentration A liquid and the blood
The mass ratio of dialysis concentration B liquid is 1:1-2.
Preferably, in a kind of lactic acid hemodialysis concentrated solution, the haemodialysis concentration A liquid includes following matter
Measure each component of concentration: sodium chloride 200-220g/L, potassium chloride 4-6g/L, calcium chloride 6-8g/L, magnesium chloride 2-4g/L and lactic acid
8-12g/L, the mass concentration that sodium bicarbonate in B liquid is concentrated in the haemodialysis is 80-90g/L.
Preferably, in a kind of lactic acid hemodialysis concentrated solution, the haemodialysis concentration A liquid includes following matter
Measure each component of concentration: sodium chloride 210.7g/L, potassium chloride 5.21g/L, calcium chloride 7.718g/L, magnesium chloride 3.558g/L and cream
Sour 9.46g/L, the mass concentration that sodium bicarbonate in B liquid is concentrated in the haemodialysis is 84.01g/L.
A kind of preparation method of above-mentioned lactic acid hemodialysis concentrated solution, comprising the following steps:
S1, configuration sodium chloride concentration be 200-220g/L, potassium chloride concentration 4-6g/L, calcium chloride concentration 6-8g/L,
A liquid is concentrated in the haemodialysis that density of magnesium chloride is 2-4g/L and lactic acid concn is 8-12g/L, spare；
B liquid is concentrated in the haemodialysis that S2, configuration sodium bicarbonate concentration are 80-90g/L, spare；
S3, haemodialysis is concentrated to A liquid, haemodialysis concentration B liquid and water for dialysis after mixing, obtains the cream
Sour hemodialysis concentrated solution.
The beneficial effects of the present invention are:
1, the production process of lactic acid hemodialysis concentrated solution of the invention will not make one to generate sense of discomfort, solve existing ice
Irritation of the acetic acid to eye and nose.
2, use lactic acid instead of glacial acetic acid in lactic acid hemodialysis concentrated solution of the invention: lactic acid odorlessness, and lactic acid bacteria
Can in vivo by breeding generate metabolic active substance, directly for host provide available essential amino acid (such as lysine with
Methionine etc.) and various vitamins (vitamin B complex and K, H etc.), the biological activity of mineral element is improved, the battalion of animal is enhanced
Metabolism is supported, growth is promoted.In addition, the growth of lactic acid bacteria makes intestinal environment in acidity, be conducive to the digestion and absorption of nutrient, reinforce
The wriggling of enteron aisle and secretion.
Further advantage, target and feature of the invention will be partially reflected by the following instructions, and part will also be by this
The research and practice of invention and be understood by the person skilled in the art.
Specific embodiment
The present invention will be further described in detail below with reference to the embodiments, to enable those skilled in the art referring to specification
Text can be implemented accordingly.
<embodiment 1>
B liquid is concentrated in a kind of lactic acid hemodialysis concentrated solution, including haemodialysis concentration A liquid and haemodialysis:
Haemodialysis concentration A liquid includes each component of following mass concentration: sodium chloride 200g/L, potassium chloride 4g/L,
Calcium chloride 6g/L, magnesium chloride 2g/L and lactic acid 8g/L, the mass concentration that sodium bicarbonate in B liquid is concentrated in the haemodialysis is 80g/
L。
A kind of preparation method of above-mentioned lactic acid hemodialysis concentrated solution, comprising the following steps:
S1, configuration sodium chloride concentration be 200g/L, potassium chloride concentration 4g/L, calcium chloride concentration 6g/L, magnesium chloride are dense
A liquid is concentrated in the haemodialysis that degree is 2g/L and lactic acid concn is 8g/L, spare；
B liquid is concentrated in the haemodialysis that S2, configuration sodium bicarbonate concentration are 80g/L, spare；
S3, haemodialysis is concentrated to A liquid, haemodialysis concentration B liquid and water for dialysis after mixing, obtains the cream
Sour hemodialysis concentrated solution.
<embodiment 2>
B liquid is concentrated in a kind of lactic acid hemodialysis concentrated solution, including haemodialysis concentration A liquid and haemodialysis:
The haemodialysis concentration A liquid includes each component of following mass concentration: sodium chloride 210.7g/L, potassium chloride
Carbonic acid in B liquid is concentrated in 5.21g/L, calcium chloride 7.718g/L, magnesium chloride 3.558g/L and lactic acid 9.46g/L, the haemodialysis
The mass concentration of hydrogen sodium is 84.01g/L.
A kind of preparation method of above-mentioned lactic acid hemodialysis concentrated solution, comprising the following steps:
S1, configuration sodium chloride concentration be 210.7g/L, potassium chloride concentration 5.21g/L, calcium chloride concentration 7.718g/L,
A liquid is concentrated in the haemodialysis that density of magnesium chloride is 3.558g/L and lactic acid concn is 9.46g/L, spare；
B liquid is concentrated in the haemodialysis that S2, configuration sodium bicarbonate concentration are 84.01g/L, spare；
S3, haemodialysis is concentrated to A liquid, haemodialysis concentration B liquid and water for dialysis after mixing, obtains the cream
Sour hemodialysis concentrated solution.
<embodiment 3>
B liquid is concentrated in a kind of lactic acid hemodialysis concentrated solution, including haemodialysis concentration A liquid and haemodialysis:
Haemodialysis concentration A liquid includes each component of following mass concentration: sodium chloride 220g/L, potassium chloride 6g/L,
Calcium chloride 8g/L, magnesium chloride 4g/L and lactic acid 12g/L, the mass concentration that sodium bicarbonate in B liquid is concentrated in the haemodialysis are
90g/L。
A kind of preparation method of above-mentioned lactic acid hemodialysis concentrated solution, comprising the following steps:
S1, configuration sodium chloride concentration be 220g/L, potassium chloride concentration 6g/L, calcium chloride concentration 8g/L, magnesium chloride are dense
A liquid is concentrated in the haemodialysis that degree is 4g/L and lactic acid concn is 12g/L, spare；
B liquid is concentrated in the haemodialysis that S2, configuration sodium bicarbonate concentration are 90g/L, spare；
S3, haemodialysis is concentrated to A liquid, haemodialysis concentration B liquid and water for dialysis after mixing, obtains the cream
Sour hemodialysis concentrated solution.
Water used in above-described embodiment is water for dialysis, and involved assay method is the ion of this field routine
Method of inspection.
Although the embodiments of the present invention have been disclosed as above, but its is not only in the description and the implementation listed
With it can be fully applied to various fields suitable for the present invention, for those skilled in the art, can be easily
Realize other modification, therefore without departing from the general concept defined in the claims and the equivalent scope, the present invention is simultaneously unlimited
In specific details and embodiment shown and described herein.
Claims (5)
1. B liquid is concentrated in a kind of lactic acid hemodialysis concentrated solution, including haemodialysis concentration A liquid and haemodialysis, it is characterised in that:
The haemodialysis concentration A liquid is by following material composition: sodium chloride, potassium chloride, calcium chloride, magnesium chloride, lactic acid and water；
The haemodialysis concentration B liquid is by following material composition: sodium bicarbonate and water.
2. a kind of lactic acid hemodialysis concentrated solution as described in claim 1, which is characterized in that A liquid is concentrated in the haemodialysis
Mass ratio with haemodialysis concentration B liquid is 1:1-2.
3. a kind of lactic acid hemodialysis concentrated solution as claimed in claim 1 or 2, which is characterized in that A is concentrated in the haemodialysis
Liquid includes each component of following mass concentration: sodium chloride 200-220g/L, potassium chloride 4-6g/L, calcium chloride 6-8g/L, magnesium chloride
2-4g/L and lactic acid 8-12g/L, the mass concentration that sodium bicarbonate in B liquid is concentrated in the haemodialysis is 80-90g/L.
4. a kind of lactic acid hemodialysis concentrated solution as claimed in claim 3, which is characterized in that A liquid is concentrated in the haemodialysis
Each component including following mass concentration: sodium chloride 210.7g/L, potassium chloride 5.21g/L, calcium chloride 7.718g/L, magnesium chloride
3.558g/L and lactic acid 9.46g/L, the mass concentration that sodium bicarbonate in B liquid is concentrated in the haemodialysis is 84.01g/L.
5. a kind of preparation method of lactic acid hemodialysis concentrated solution as claimed in claim 3, which is characterized in that including following step
It is rapid:
S1, configuration sodium chloride concentration be 200-220g/L, potassium chloride concentration 4-6g/L, calcium chloride concentration 6-8g/L, chlorination
A liquid is concentrated in the haemodialysis that magnesium density is 2-4g/L and lactic acid concn is 8-12g/L, spare；
B liquid is concentrated in the haemodialysis that S2, configuration sodium bicarbonate concentration are 80-90g/L, spare；
S3, haemodialysis is concentrated to A liquid, haemodialysis concentration B liquid and water for dialysis after mixing, obtains the lactacidemia
Liquid dialysis concentrate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811613320.9A CN109512837A (en) | 2018-12-27 | 2018-12-27 | A kind of lactic acid hemodialysis concentrated solution and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811613320.9A CN109512837A (en) | 2018-12-27 | 2018-12-27 | A kind of lactic acid hemodialysis concentrated solution and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109512837A true CN109512837A (en) | 2019-03-26 |
Family
ID=65797148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811613320.9A Pending CN109512837A (en) | 2018-12-27 | 2018-12-27 | A kind of lactic acid hemodialysis concentrated solution and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109512837A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110063965A (en) * | 2019-06-04 | 2019-07-30 | 吉林省富生医疗器械有限公司 | A kind of haemodialysis concentrate |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251437B1 (en) * | 1999-07-13 | 2001-06-26 | Minntech Corporation | Liquid/powder acid concentrate for dialysate and a method of making the same |
| CN1919363A (en) * | 2006-09-15 | 2007-02-28 | 天津市肾友达医疗设备技术开发有限公司 | Novel dialytic concentrating preparation |
-
2018
- 2018-12-27 CN CN201811613320.9A patent/CN109512837A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251437B1 (en) * | 1999-07-13 | 2001-06-26 | Minntech Corporation | Liquid/powder acid concentrate for dialysate and a method of making the same |
| CN1919363A (en) * | 2006-09-15 | 2007-02-28 | 天津市肾友达医疗设备技术开发有限公司 | Novel dialytic concentrating preparation |
Non-Patent Citations (1)
| Title |
|---|
| 刘子栋: "《临床血液净化手册》", 31 January 2016 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110063965A (en) * | 2019-06-04 | 2019-07-30 | 吉林省富生医疗器械有限公司 | A kind of haemodialysis concentrate |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0716607B1 (en) | Biochemically balanced peritoneal dialysis solutions | |
| CN108289987B (en) | Method for extracorporeal circulation carbon dioxide removal | |
| Park et al. | Effect of pulmonary support using extracorporeal membrane oxygenation for adult liver transplant recipients with respiratory failure | |
| DK165734B (en) | Dialysis liquid | |
| JP2009515948A (en) | Corrosion-preventing coating agent composition containing organoclay and method for producing the same | |
| CN109512837A (en) | A kind of lactic acid hemodialysis concentrated solution and preparation method thereof | |
| Sturov et al. | Diagnostics of erythrocytes’ microrheological features and early abnormalities of rats in the model of experimental hypertension development | |
| Chamney | Renal care: six essentials for a haemodialysis patient | |
| CN109528762A (en) | A kind of leucine hemodialysis concentrated solution and preparation method thereof | |
| CN109528760A (en) | A kind of Icodextrin peritoneal dialysis solution and preparation method thereof | |
| FR2777190B1 (en) | EXTRACTION PROCESS, IDENTIFICATION OF THE ACTIVE INGREDIENTS CONTAINED IN THE INTERNAL AND EXTERNAL SHELL OF SEA MOLLUSCS, THEIR USE IN PEOPLE-BASED THERA, DIAGNOSIS AND COSMETIC PREPARATIONS | |
| CN103648576A (en) | Method of producing substances with supersaturated gas, transdermal delivery device thereof, and uses thereof | |
| CN103800285A (en) | Sodium bicarbonate injection and preparation method thereof | |
| CN104434959A (en) | Dialysis concentrate containing vitamins | |
| WO2021223732A1 (en) | Blood purification concentrate | |
| Saleh | Sepsis-associated renal salt wasting: how much is too much? | |
| JP2815457B2 (en) | Organic calcium bath liquid | |
| Gilmour et al. | Apparent diffusion limitations on branchial CO2 transfer are revealed by severe experimental anaemia in brown bullhead (Ameiurus nebulosus) | |
| Ehrich | Acute renal failure in infants and children | |
| RU2732765C1 (en) | Method of correction of reperfusion ischemic injury in partial nephrectomy for localized cancer in conditions of thermal ischemia | |
| TWI373339B (en) | Pharmaceutical composition for use in hemofiltration or hemodialysis | |
| Agishi | Beyond a Boundary Between the Scientific Artificial Organ World and the Nonscientific Spiritual World. | |
| Semenenko et al. | METABOLIC AND PATHOMORPHOLOGICAL ASPECTS OF THE HEPATOPROTECTIVE ACTIVITY OF SELEPHLAN AGAINST THE BACKGROUND OF THE DEVELOPMENT OF ACUTE MODEL HEPATITIS IN POULTRY | |
| Seyidova | Water-Salt Homeostasis of the Human Body and Electrolytic Composition of the Internal Liquid Environment | |
| Keys | The properties of the gill membranes of fishes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190326 |